Pelthos Therapeutics Inc. Gain (Loss) on Condemnation
Pelthos Therapeutics Inc. (PTHS) reported Gain (Loss) on Condemnation of $363.09 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnCondemnation · last filed 2025-03-27
- Pelthos Therapeutics Inc. gain (loss) on condemnation for the quarter ending 2024-12-31 was $0.00.
- Pelthos Therapeutics Inc. gain (loss) on condemnation for the quarter ending 2024-09-30 was $363.09K.
- Pelthos Therapeutics Inc. gain (loss) on condemnation for fiscal 2024 was $363.09K.
| Period end | Gain (Loss) on Condemnation 3 month | Gain (Loss) on Condemnation 6 month | Gain (Loss) on Condemnation 9 month | Gain (Loss) on Condemnation 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $363.09K derived: sum of 2 quarters · filed 2025-03-27 | $363.09K 10-K · filed 2025-03-27 | |
| 2024-09-30 | $363.09K 10-Q · filed 2024-11-13 | $363.09K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |